The deal priced below last closing price of $6.03. Goldman Sachs and JPMorgan are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- Bluebird Bio announces 20M share offering of common stock
- Bluebird Bio to sell second Zynteglo PRV for $95M
- Bluebird Bio appoints Joseph Vittiglio, JD, chief business and legal officer
- Bluebird Bio completes sale pf PRV to Argenx
- FDA removing lovo-cel partial hold a positive for Bluebird, says Morgan Stanley